301015.SZ
百洋医药
SZSE · Healthcare · F 批发零售 · CN
CNY 24.87
−3.83%Aug 28, 2026, 12:01 UTC
Baheal Pharmaceutical plans to invest 40 million yuan in Tianjin Jikun Pharmaceutical Technology Co., Ltd., increasing its stake to 25.44%.
Source:Aug 28, 2026, 10:58 UTC
Baiyang Pharmaceutical announced its 2026 first-half results: revenue of 3.56 billion yuan, down 5.11% year-on-year; net profit attributable to shareholders of 225 million yuan, up 37.72% year-on-year.
Source:Aug 28, 2026, 10:58 UTC
Baiyang Pharmaceutical announced plans to publicly issue H shares and list on the Main Board of the Hong Kong Stock Exchange.
Source:Jul 7, 2026, 00:42 UTC
Baheal Medical's first third-party ZAP-X radiosurgery center at Peking University International Hospital completed its first clinical treatment, marking the formal entry of ZAP-X into large-scale clinical application.
Source: